JP2009502138A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502138A5
JP2009502138A5 JP2008523010A JP2008523010A JP2009502138A5 JP 2009502138 A5 JP2009502138 A5 JP 2009502138A5 JP 2008523010 A JP2008523010 A JP 2008523010A JP 2008523010 A JP2008523010 A JP 2008523010A JP 2009502138 A5 JP2009502138 A5 JP 2009502138A5
Authority
JP
Japan
Prior art keywords
irna agent
modified
sense strand
agent according
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008523010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502138A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028488 external-priority patent/WO2007014077A2/en
Publication of JP2009502138A publication Critical patent/JP2009502138A/ja
Publication of JP2009502138A5 publication Critical patent/JP2009502138A5/ja
Pending legal-status Critical Current

Links

JP2008523010A 2005-07-21 2006-07-21 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法 Pending JP2009502138A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70147005P 2005-07-21 2005-07-21
US72683805P 2005-10-14 2005-10-14
US74831605P 2005-12-07 2005-12-07
PCT/US2006/028488 WO2007014077A2 (en) 2005-07-21 2006-07-21 Rnai modulation of the rho-a gene and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011170509A Division JP2011250796A (ja) 2005-07-21 2011-08-03 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Publications (2)

Publication Number Publication Date
JP2009502138A JP2009502138A (ja) 2009-01-29
JP2009502138A5 true JP2009502138A5 (https=) 2011-03-24

Family

ID=37683845

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008523010A Pending JP2009502138A (ja) 2005-07-21 2006-07-21 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
JP2011170509A Pending JP2011250796A (ja) 2005-07-21 2011-08-03 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
JP2011282081A Withdrawn JP2012061007A (ja) 2005-07-21 2011-12-22 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011170509A Pending JP2011250796A (ja) 2005-07-21 2011-08-03 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
JP2011282081A Withdrawn JP2012061007A (ja) 2005-07-21 2011-12-22 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Country Status (6)

Country Link
US (3) US7772200B2 (https=)
EP (2) EP2230305A1 (https=)
JP (3) JP2009502138A (https=)
AU (2) AU2006272808C1 (https=)
CA (1) CA2607668A1 (https=)
WO (2) WO2007014077A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272808C1 (en) * 2005-07-21 2010-10-21 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Rho-A gene and uses thereof
RU2487716C2 (ru) * 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US20110020359A1 (en) * 2009-07-24 2011-01-27 California Institute Of Technology Methods and compositions for treating neuronal damage or degeneration
WO2011021221A2 (en) * 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
WO2011057171A1 (en) * 2009-11-08 2011-05-12 Quark Pharmaceuticals, Inc. METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
CN103097534B (zh) * 2010-06-24 2017-07-28 夸克制药公司 针对rhoa的双链rna化合物及其用途
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US11071791B2 (en) 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
GB201903804D0 (en) * 2019-03-20 2019-05-01 Univ Leicester Methods and kits for detecting rhoa mutations
WO2025212926A1 (en) * 2024-04-05 2025-10-09 University Of Massachusetts Aav-mediated rhoa knockdown

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396719B1 (en) 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US7069634B1 (en) * 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US7189222B2 (en) * 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
WO1999053945A1 (en) 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
US6410323B1 (en) * 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US6945969B1 (en) * 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US6551290B1 (en) 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7482138B2 (en) * 2001-12-28 2009-01-27 The Trustees Of Columbia University In The City Of New York PAK5-related compositions and methods
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
US20040191291A1 (en) 2003-03-28 2004-09-30 Masaya Tohyama Composition and method for nerve regeneration
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
JP4991288B2 (ja) 2003-04-17 2012-08-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
EP1486564A1 (de) 2003-06-13 2004-12-15 Ribopharma AG SiRNA mit erhöhter Stabilität in Serum
FR2857768B1 (fr) 2003-07-18 2006-01-06 Atmel Grenoble Sa Procede d'acquisition d'image d'empreinte digitale
EP1802755A1 (en) * 2004-10-22 2007-07-04 Neuregenix Limited Neuron regeneration
JP2008537551A (ja) * 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
AU2006272808C1 (en) * 2005-07-21 2010-10-21 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Rho-A gene and uses thereof
NZ571568A (en) * 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer

Similar Documents

Publication Publication Date Title
JP2011250796A5 (https=)
JP2009502138A5 (https=)
US5532130A (en) Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
JP4584987B2 (ja) Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
CA2562685C (en) Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
AU2005327517B2 (en) Oligonucleotides comprising a non-phosphate backbone linkage
JP7348922B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP2021003113A (ja) 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド
JP2005522997A (ja) 交代セグメントを含むオリゴヌクレオチド及びその用途
CN102686729B (zh) 用于治疗hsf1相关疾病的有机组合物
JP2008523157A5 (https=)
CA2921459A1 (en) Oligonucleotides targeting euchromatin regions of genes
JP2005517436A5 (https=)
TW202006138A (zh) Fubp1抑制劑用於治療b型肝炎病毒感染之用途
CN115819484A (zh) 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
JP2024515576A (ja) 修飾ヌクレオシド
Yamada et al. Synthesis of 2′-O-[2-(N-methylcarbamoyl) ethyl] ribonucleosides using oxa-Michael reaction and chemical and biological properties of oligonucleotide derivatives incorporating these modified ribonucleosides
JP2006502243A5 (https=)
JP2021533118A (ja) ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド
Seio et al. Synthesis and properties of cationic 2′-O-[N-(4-aminobutyl) carbamoyl] modified oligonucleotides
RU2008121953A (ru) Ирнк-ингибирование репликации вируса гриппа
JP2022521510A (ja) ホスホノアセテートギャップマー型オリゴヌクレオチド
Park et al. Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents
WO2024228398A1 (ja) グアニン四重鎖構造を誘導するための核酸剤
Berk Alternative scaffolds for systemic delivery of small interfering RNAs